Literature DB >> 9528833

Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.

T Nakano1, A P Chahinian, M Shinjo, A Tonomura, M Miyake, N Togawa, K Ninomiya, K Higashino.   

Abstract

The relationship between interleukin 6 (IL-6) levels and clinical parameters was studied in 25 patients with malignant pleural mesothelioma. The serum levels of IL-6, C-reactive protein, alpha1-acid glycoprotein and fibrinogen were significantly higher in mesothelioma than in lung adenocarcinoma with cytology-positive pleural effusion. Serum IL-6 levels correlated with the levels of the acute-phase proteins. We demonstrated a high incidence of thrombocytosis (48%) and a significant correlation between platelet count and the serum IL-6 level. The level of IL-6 in the pleural fluid of patients with mesothelioma was significantly higher than in the pleural fluid of patients with adenocarcinoma, and was about 60-1400 times higher than in the serum. However, even higher levels of IL-6 in the pleural fluid and of thrombocytosis were found in patients with tuberculous pleurisy. These results indicate that large amounts of IL-6 from the pleural fluid of patients with mesothelioma leak into the systemic circulation and induce clinical inflammatory reactions. These profiles are not specific to mesothelioma as similar profiles are found in patients with tuberculous pleurisy. However, the detection of a markedly increased level of IL-6 in pleural fluid argues against a diagnosis of adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9528833      PMCID: PMC2150109          DOI: 10.1038/bjc.1998.150

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  Acute-phase proteins and interleukin 6 serum level in head and neck cancer.

Authors:  O Gallo; A M Gori; M Attanasio; F Martini; G Paola; O F Storchi; R Abbate
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1992-12

Review 2.  The evidence for interleukin-6 as an autocrine growth factor in malignancy.

Authors:  S Akira; T Kishimoto
Journal:  Semin Cancer Biol       Date:  1992-02       Impact factor: 15.707

3.  Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

Authors:  J Y Blay; S Negrier; V Combaret; S Attali; E Goillot; Y Merrouche; A Mercatello; A Ravault; J M Tourani; J F Moskovtchenko
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

4.  Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.

Authors:  H Bielefeldt-Ohmann; A L Marzo; R P Himbeck; A G Jarnicki; B W Robinson; D R Fitzpatrick
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

5.  Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature.

Authors:  D Schmitter; B Lauber; B Fagg; R A Stahel
Journal:  Int J Cancer       Date:  1992-05-08       Impact factor: 7.396

6.  Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment.

Authors:  G Monti; M C Jaurand; I Monnet; P Chretien; L Saint-Etienne; L Zeng; A Portier; P Devillier; P Galanaud; J Bignon
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

7.  Increased secretion of interleukin-6 in malignant mesothelioma cells from a patient with marked thrombocytosis.

Authors:  M Higashihara; S Sunaga; T Tange; H Oohashi; K Kurokawa
Journal:  Cancer       Date:  1992-10-15       Impact factor: 6.860

8.  Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6.

Authors:  M R Duncan; B Berman
Journal:  J Invest Dermatol       Date:  1991-10       Impact factor: 8.551

9.  Interleukin-6-producing pheochromocytoma.

Authors:  K Suzuki; A Miyashita; Y Inoue; S Iki; H Enomoto; Y Takahashi; T Takemura
Journal:  Acta Haematol       Date:  1991       Impact factor: 2.195

10.  Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.

Authors:  E Tartour; T Dorval; V Mosseri; L Deneux; C Mathiot; H Brailly; F Montero; I Joyeux; P Pouillart; W H Fridman
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

View more
  31 in total

1.  Mesothelioma and venous thrombosis.

Authors:  Mehlika Isildak; Gulay Sain Guven; Salih Emri
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

2.  Budd-Chiari syndrome in pleural mesothelioma.

Authors:  Bora Aktas; Oguz Uskudar; Sahin Coban; Elif Aktas
Journal:  J Gastrointest Cancer       Date:  2011-12

Review 3.  In vitro experimental models of mesothelioma revisited.

Authors:  Anand Singh; Nathanael Pruett; Chuong D Hoang
Journal:  Transl Lung Cancer Res       Date:  2017-06

4.  Inflammation in malignant mesothelioma - friend or foe?

Authors:  Anthony Linton; Nico van Zandwijk; Glen Reid; Stephen Clarke; Christopher Cao; Steven Kao
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 5.  Thrombocytosis as a prognostic marker in gastrointestinal cancers.

Authors:  Ioannis A Voutsadakis
Journal:  World J Gastrointest Oncol       Date:  2014-02-15

6.  Potential role of interleukin 6 in reactive thrombocytosis and acute phase response in pulmonary tuberculosis.

Authors:  E Unsal; S Aksaray; D Köksal; T Sipit
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

Review 7.  Serum mesothelin and other biomarkers: what have we learned in the last decade?

Authors:  Alfonso Cristaudo; Alessandra Bonotti; Giovanni Guglielmi; Poupak Fallahi; Rudy Foddis
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

8.  C-reactive protein as an acute phase protein in cancer patients.

Authors:  Murat Bolayirli; Hande Turna; Timur Orhanoğlu; Resat Ozaras; Mahmut Ilhan; Mustafa Ozgüroğlu
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

9.  [Mesotheliomas with leucocytic infiltration].

Authors:  P Dorfmüller; M Krismann; K-M Müller
Journal:  Pathologe       Date:  2004-09       Impact factor: 1.011

Review 10.  Peritoneal mesothelioma.

Authors:  R N Taub; M L Keohan; J C Chabot; K S Fountain; M Plitsas
Journal:  Curr Treat Options Oncol       Date:  2000-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.